| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | -105,3 k € | +8.4% | -114,9 k € | +38.4% | -186,6 k € | |
| EBITDA | -707,9 k € | -58.2% | -447,4 k € | -33.0% | -336,3 k € | |
| Operating profit | -742,9 k € | -62.1% | -458,3 k € | -35.6% | -338,0 k € | |
| Profit/loss | -690,5 k € | -52.9% | -451,6 k € | -36.7% | -330,5 k € | |
| Equity | 3,7 M € | +771.2% | 429,2 k € | -51.3% | 880,7 k € | |
| Total assets | 4,0 M € | +560.0% | 600,1 k € | -55.5% | 1,3 M € | |
| Cash | 171,9 k € | -52.9% | 365,4 k € | -52.0% | 760,4 k € | |
| Debts | 222,2 k € | +59.0% | 139,7 k € | -70.1% | 467,2 k € | |
Source: Belgian Official Gazette
Private limited company · Charleroi · incorporated on 28/10/2022
Private limited company loss-making in the latest fiscal year. Cash position declining (-52.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
CANCER STATE THERAPEUTICS is a Private limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi.